Related Experiment Videos
Transdermal dihydrotestosterone therapy and its effects on patients with microphallus
1Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
The Journal of Urology
|August 1, 1993
Summary
Transdermal dihydrotestosterone therapy effectively treats microphallus in young patients, promoting penile growth. This treatment is safe and shows promise, even for those unresponsive to testosterone therapy.
Area of Science:
- Endocrinology
- Pediatric Urology
Background:
- Microphallus is a condition requiring effective therapeutic interventions.
- Previous treatments may have limitations or varying success rates.
Purpose of the Study:
- To evaluate the efficacy and safety of transdermal dihydrotestosterone (DHT) therapy for microphallus.
- To assess DHT's impact on penile growth, hormonal function, and other physiological parameters.
Main Methods:
- 22 patients with microphallus received DHT gel for 8 weeks.
- Dosing varied by age (12.5 mg for <10 years, 25 mg for >10 years).
- Evaluations included penile/prostatic growth, hormonal axis, lipid metabolism, and bone age.
Main Results:
- All patients showed penile growth, with faster growth in the initial 4 weeks.
- Four patients who failed testosterone therapy responded to DHT.
- Transient pituitary-gonadal axis suppression and effects on lipid metabolism and sex hormone-binding globulin were observed.
- Bone age and height velocity were not significantly affected.
Conclusions:
- Transdermal dihydrotestosterone therapy is an effective treatment for microphallus.
- The therapy demonstrates a favorable safety profile with manageable side effects.